Vimarsana
Biggest News Aggregation in the World

Page 2 - New Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from New Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In New Technologies Today - Breaking & Trending Today

Nokia CEO Makes First 3D Spatial Audio Phone Call - Vimarsana News

Nokia CEO Makes First 3D Spatial Audio Phone Call

ESPOO (dpa-AFX) - Nokia (NOK) has successfully demonstrated the 'world's first cellular call using new Immersive Voice and Audio Services or IVAS' codec, making a breakthrough in voice communication

Nokia conducts first public 5G call using 3D spatial audio - Vimarsana News

Nokia conducts first public 5G call using 3D spatial audio

Lundmark was famously on hand back in 1991 when the Finnish phone giant conducted the first commercial call using the global system for mobile communications, or GSM...

New Tech, Longer Range, and Lower Prices Keep Rivian in the Game - Vimarsana News

New Tech, Longer Range, and Lower Prices Keep Rivian in the Game

Impressive powertrain, battery, and electronics updates aim to keep Rivian ahead of the pack.

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) - Vimarsana News

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic...

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in - Vimarsana News

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with...